Revance Therapeutics Inc (NASDAQ:RVNC) has been assigned a consensus rating of “Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $30.67.
A number of analysts recently commented on the stock. Mizuho reiterated a “buy” rating and issued a $34.00 target price on shares of Revance Therapeutics in a research note on Tuesday, November 5th. Zacks Investment Research cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. Wells Fargo & Co upgraded shares of Revance Therapeutics from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $12.50 to $20.00 in a research note on Wednesday, October 30th. ValuEngine upgraded shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, William Blair reiterated an “outperform” rating on shares of Revance Therapeutics in a research note on Tuesday, August 6th.
A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in Revance Therapeutics by 47.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,330,973 shares of the biopharmaceutical company’s stock worth $17,263,000 after buying an additional 428,900 shares during the last quarter. Aperio Group LLC raised its position in Revance Therapeutics by 166.2% during the 2nd quarter. Aperio Group LLC now owns 34,551 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 21,570 shares during the last quarter. M&T Bank Corp purchased a new position in Revance Therapeutics during the 2nd quarter worth approximately $153,000. DekaBank Deutsche Girozentrale purchased a new position in Revance Therapeutics during the 2nd quarter worth approximately $1,010,000. Finally, Sio Capital Management LLC raised its position in Revance Therapeutics by 58.6% during the 2nd quarter. Sio Capital Management LLC now owns 403,664 shares of the biopharmaceutical company’s stock worth $5,236,000 after buying an additional 149,083 shares during the last quarter. Institutional investors own 94.49% of the company’s stock.
Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.96). The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.40 million. Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 87.59%. Equities research analysts forecast that Revance Therapeutics will post -3.64 earnings per share for the current fiscal year.
About Revance Therapeutics
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Read More: Inverted Yield Curve
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.